Immunome stock sinks after testing of its experimental Covid-19 'cocktail' delayed by FDA

Immunome filed an investigational new drug application with the FDA in late November seeking approval to begin human testing of the Covid-19 therapy.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.